New Hope for PKD Patients: IMPEDE-PKD Research Study
A ground-breaking research study is underway to investigate whether the diabetes drug metformin can slow the progression of Polycystic Kidney Disease (PKD), focusing on the most common inherited form: Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Understanding ADPKD: A Leading Cause of Kidney Failure
Marked by the growth of fluid-filled cysts in the kidneys, ADPKD is the 4th leading cause of kidney failure, with over 70% of those affected requiring kidney replacement therapy by age 58 (UK RaDaR data). With limited treatment options currently available, finding ways to slow cyst growth early is crucial to preventing irreversible kidney damage.
Metformin’s Potential to Slow Cyst Growth
Metformin, commonly used to treat diabetes, has shown promise in initial studies by potentially blocking signals that drive cyst growth. Recent clinical trials have also confirmed that metformin is safe for use in ADPKD patients.
The IMPEDE-PKD Study: A Global Effort
The IMPEDE-PKD trial will involve 1,174 participants from the UK, USA, Australia, and New Zealand, with 300 patients being recruited from the UK.
How the Study Will Be Conducted
In the first phase of the study, all participants will be gradually adjusted to an optimal metformin dosage. Afterwards, they will continue taking either metformin or a placebo for two years. Kidney function, pain levels, and quality of life will be closely monitored. As a double-blind trial, neither participants nor researchers will know who is receiving the medication or the placebo.
Aiming to Transform ADPKD Treatment
The study’s goal is to assess whether metformin can delay the progression of kidney disease and reduce the need for kidney replacement therapy. With limited treatment options available to slow progression, new approaches are urgently needed. If successful, this research could transform the treatment landscape for those living with ADPKD.
Recruitment in the UK is expected to begin later in 2025, marking a promising step toward improved care.
For those interested in the study’s progress or in participating, stay tuned for additional information in the coming months or get in touch: [email protected]
Medical Illustration: Aimee Hutchinson
Looking Ahead: PKD Research and Support
|
Exciting UK research into PKD is underway. Teams at Sheffield and Leeds are looking at how to slow cyst growth and kidney enlargement, including organoid drug testing and genetic studies. The new PKD Partnership, led by the PKD Charity and Kidney Research UK, is poised to accelerate the development of effective treatments and improve the lives of those affected by PKD. By combining the strength of researchers, clinicians, patients and funders, the partnership aims to turn scientific progress into real-world change — faster. Learn more about the IMPEDE-PKD study and watch our PKD Live Q&A with Dr. Ragada El-Damanawi, Consultant Nephrologist at the Sheffield Kidney Institute and UK Chief Investigator for IMPEDE-PKD And coming soon: the launch of a brand-new PKD Research Hub — a space where patients can directly shape future studies and clinical trials. If you'd like to be part of that, we'd love to hear from you. |
If you would like to speak to us about what support we can offer you or a loved one, please visit PKD Support or contact us today and speak to a member of our team.
ADPKD, Research, PKD, PKDTreatment
- Hits: 21171